MRI-detected signs of cardiac remodeling may tell clinicians a thing or two about a patient's odds of developing certain cancers. Changes in heart muscle mass, for example, were linked to an increased risk of breast cancer.
A vast majority of patient deaths in the first year after TAVR have nothing to do with heart health. Could care teams be doing more to identify high-risk patients?
